Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

BMJ : British Medical Journal
Ling LiXin Sun

Abstract

To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of heart failure or hospital admission for heart failure in patients with type 2 diabetes. Systematic review and meta-analysis of randomised and observational studies. Medline, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov searched up to 25 June 2015, and communication with experts. Randomised controlled trials, non-randomised controlled trials, cohort studies, and case-control studies that compared DPP-4 inhibitors against placebo, lifestyle modification, or active antidiabetic drugs in adults with type 2 diabetes, and explicitly reported the outcome of heart failure or hospital admission for heart failure. Teams of paired reviewers independently screened for eligible studies, assessed risk of bias, and extracted data using standardised, pilot tested forms. Data from trials and observational studies were pooled separately; quality of evidence was assessed by the GRADE approach. Eligible studies included 43 trials (n=68,775) and 12 observational studies (nine cohort studies, three nested case-control studies; n=1,777,358). Pooling of 38 trials reporting heart failure provided low quality evidence for a poss...Continue Reading

Citations

Jan 19, 2018·Journal of Biological Engineering·Shihui FuLeiming Luo
Dec 28, 2018·Circulation·Faiez Zannad, Patrick Rossignol
Feb 28, 2019·Expert Opinion on Drug Safety·Vasilios G AthyrosMichael Doumas
Aug 17, 2018·The Journal of Clinical Endocrinology and Metabolism·Pai-Feng HsuChih-Cheng Hsu
Sep 29, 2019·Biomarkers in Medicine·Óscar M PeiróAlfredo Bardají
Aug 27, 2019·Current Topics in Medicinal Chemistry·Shihui FuJuelin Deng
Jul 6, 2017·Current Opinion in Cardiology·Harpreet S BajajSubodh Verma
May 22, 2020·Circulation Research·Rebecca H Ritchie, E Dale Abel
Feb 23, 2020·Clinical and Experimental Pharmacology & Physiology·Martin CaprndaVladimir Krasnik
Nov 14, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Koh OnoUNKNOWN ABLE-MET Investigators
Nov 3, 2016·Current Opinion in Lipidology·Kenneth Cusi
Feb 23, 2018·Expert Opinion on Drug Safety·André Jacques Scheen
Oct 8, 2016·Cardiovascular Diabetology·Oliver SchnellUNKNOWN D&CVD EASD Study Group
Sep 30, 2020·Expert Opinion on Pharmacotherapy·Kazuki Orime, Yasuo Terauchi
Oct 21, 2016·Endocrine·Dario GiuglianoKatherine Esposito
Sep 7, 2016·Expert Opinion on Pharmacotherapy·Hiroyuki ItoMariko Abe
Aug 10, 2016·Archives of Pharmacal Research·Eun Ju Bae
Oct 19, 2017·Cardiovascular Research·Oliver J ZiffSean M Davidson
Jan 24, 2018·Heart Failure Reviews·Alberto PalazzuoliRanuccio Nuti
Dec 23, 2017·BioMed Research International·Mona P NasrallahMarwan M Refaat
Mar 2, 2019·Cardiovascular Diabetology·Atsushi Tanaka, Koichi Node
Jun 5, 2016·Cardiovascular Diabetology·Gianluca Perseghin, Anna Solini
Feb 27, 2017·Diabetes & Metabolism Journal·Manoja K BrahmaAdam R Wende
Feb 6, 2017·Cardiovascular Diabetology·James Xu, Rohan Rajaratnam
Jun 8, 2017·Cardiovascular Diabetology·Jing-Wei LiTian-Wen Han

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00094770
NCT00103857
NCT00121641
NCT00121667
NCT00286442
NCT00286468
NCT00295633
NCT00327015
NCT00395343
NCT00482729

Software Mentioned

MOOSE

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.